Two Phase 3 clinical trials testing Tyvaso (treprostinil) in people with idiopathic pulmonary fibrosis (IPF) both met their main goals, showing that the inhalation therapy significantly outperformed a placebo at slowing the decline in lung function among IPF patients. With these data in hand, Tyvaso’s developer, United…